

Is biopsy the next step?

Find out with Prostate Health Index from ARUP Laboratories.

Prostate Health Index (*phi*) is a safe, less-invasive step in the process of diagnosing prostate cancer. It's a simple, FDA-approved blood test that uses an algorithm to assess total PSA, free PSA, and p2PSA.

Using *phi* as part of a multivariable diagnostic process can significantly reduce the number of unnecessary biopsies.

Be confident in your diagnostic decisions about prostate cancer.

Prostate Health Index (*phi*)

	PROSTATE HEALTH INDEX (<i>phi</i>) (3000134)	4KSCORE (2014059)
Ordering recommendation	<ul style="list-style-type: none">Men aged 50 or olderTotal PSA between 4 and 10 ng/mLDRE not suspicious for cancer (specimens for testing should be drawn prior to DRE or other prostate manipulations)	<ul style="list-style-type: none">Men aged 40-80No DRE in previous 4 daysNo previous prostate cancer diagnosisNo treatment of BPH, invasive urologic procedure with secondary PSA eval, or 5-ARI therapy in past 6 months
Specimen type	1.5 mL serum (critical frozen)	4 mL serum (refrigerated or frozen)
Testing location	In-house at ARUP, under standardized conditions in a CLIA- and CAP-certified lab	Sendout
Turnaround time	Results within 24 hours of scheduled run	3–6 days
FDA approval	YES	NO

For pricing information, please contact your ARUP Account Executive.



*A nonprofit enterprise of the University of Utah
and its Department of Pathology*

For more information about
prostate cancer screening, visit
arupconsult.com/content/prostate-cancer.

(800) 242-2787 | aruplab.com/phi